Document is current
Any future updates will be listed below
-
Authors
Lamy, Sébastien
Fenni, Raphaël
Tavitian, Suzanne
Lapierre, Léopoldine
Leguay, Thibaut
Galtier, Jean
Sarry, Audrey
De-Grande, Anne-Charlotte
Berard, Emilie
Pigneux, Arnaud
Récher, Christian
Dumas, Pierre-Yves
Bertoli, Sarah
-
Funding
Funding for this research was provided by:
Ligue Contre le Cancer, France
GIRCI SOHO
- License Information
-
More Information
Article History
Received: 19 December 2025
Accepted: 23 February 2026
First Online: 6 March 2026
Declarations
:
: The authors declare the following conflict of interest : PYD declares a consulting or advisory role with Daiichi-Sankyo, Jazz Pharmaceutical, Astellas, Abbvie, Celgene, Janssen, BMS, Gilead, Novartis, and Servier. CR declares a consulting or advisory role with Abbvie, Amgen, Astellas, BMS, Boehringer, Jazz Pharmaceuticals and Servier, and received research funding from Abbvie, Amgen, Astellas, BMS, Iqvia and Jazz Pharmaceuticals. SB declares a consulting or advisory role with Abbvie, Astellas, BMS-Celgene, Jazz Pharmaceuticals and Servier.
: The cohort has been approved by the national ethical authorities (CCTIRS (ref 15.319) and CNIL (ref 915285)).
: All patients included in the DATAML cohort received and signed the information notice to express their non-opposition for the use of their data for research.
